Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.10.18
Views: 244
Rating:

Dr Maria Vittoria Dieci - University of Padua, Padova, Italy

Dr Maria Vittoria Dieci speaks with ecancer at ESMO 2018 in Munich about results from a sub study from the larger shortHER trial where they looked at tumour-infiltrating lymphocytes as an independent prognostic factor for early HER2 positive breast cancer patients.

Dr Dieci found a significant association between increased tumour-infiltrating lymphocytes and improved metastasis free survival.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation